AbCellera Biologics Inc 2024年度报告

Dear AbCellera Shareholders: 2024 was a year of significant change for AbCellera. In late 2023,we decided to transition from aplatform and partnership company to a clinical-stage biotech.Since then, our focus has been on buildingour internal pipeline and completing investments in our platform, while improving efficiency andmaintaining a strong cash position. In 2024, we achieved the following milestones: •We advanced two programs, ABCL635 and ABCL575, which are now positioned for CTA filingsin 2025. Behind these, we are advancing a robust pipeline of internal programs in discovery;•We completed our move into our new headquarters and are on track to bring our clinicalmanufacturing facility online this year. Importantly, we expect significant investments in ourplatform and facilities to be complete in the first half of 2025; and•We closed2024with over $800 million in available liquidity, and are in a strong position toexecute on our strategy. From here, the most important strategic question is howwe allocateour time and our capital to build ourpipeline.We areexplicitly indication agnostic. We are open to all opportunities where we perceive anunmet need and an outsized chance of succeeding in the clinic and in the market. We assessopportunitiesby answering four central questions: •Do we have conviction in the science?•Do we see a large unmet need and commercial opportunity?•Is there a case for strong differentiation so we can win in the market?•Is there a clear development path? Lookingat2025,this is an exciting time at AbCellera andwe are focused on entering the clinic andbringing our manufacturing capabilities online. Our priorities for the year are: •To initiate Phase 1 Clinical Trials for ABCL635 and ABCL575;•To nominate additional development candidate(s) for CTA-enabling studies;•To complete platform investments; and•To start activities in our new clinical manufacturing facility. We invite you to attend the Annual Meeting of Shareholders of AbCellera Biologics Inc. to be heldvirtually on Thursday, June 12, 2025, at 9:00 A.M. Pacific Time. Whether or not you plan toattend, theprompt execution and return of your proxy card will both assure your shares are represented at themeeting and minimize the cost of proxy solicitation. Thank you for your continued support. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024OR oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934FOR THE TRANSITION PERIOD FROMTO Commission File Number 001-39781 AbCellera Biologics Inc. (Exact name of Registrant as specified in its Charter) Registrant’s telephone number, including area code: (604) 559-9005 Securities registered pursuant to Section 12(b) of the Act: The Nasdaq Stock Market Securities registered pursuant to Section 12(g) of the Act:None Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YesxNoo Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YesoNox Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YesxNoo Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit suchfiles). YesxNoo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any newor revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.o Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internalcontrol over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm thatprepared or issued its audit report.xIf securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant